Columbus Circle Investors lifted its stake in LHC Group, Inc. (NASDAQ:LHCG) by 48.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 81,152 shares of the health services provider’s stock after acquiring an additional 26,496 shares during the quarter. Columbus Circle Investors owned 0.26% of LHC Group worth $8,358,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of LHCG. California Public Employees Retirement System lifted its holdings in shares of LHC Group by 2.0% in the 1st quarter. California Public Employees Retirement System now owns 49,086 shares of the health services provider’s stock worth $3,022,000 after acquiring an additional 944 shares during the last quarter. Cubist Systematic Strategies LLC lifted its holdings in LHC Group by 36.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 2,636 shares of the health services provider’s stock worth $162,000 after buying an additional 711 shares in the last quarter. Xact Kapitalforvaltning AB acquired a new stake in LHC Group during the 1st quarter worth approximately $250,000. Allianz Asset Management GmbH lifted its holdings in LHC Group by 12.8% during the 1st quarter. Allianz Asset Management GmbH now owns 141,336 shares of the health services provider’s stock worth $8,701,000 after buying an additional 16,073 shares in the last quarter. Finally, Fisher Asset Management LLC acquired a new stake in LHC Group during the 2nd quarter worth approximately $3,234,000. Hedge funds and other institutional investors own 86.24% of the company’s stock.
In other LHC Group news, COO Donald Dwayne Stelly sold 2,756 shares of the stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $99.32, for a total value of $273,725.92. Following the sale, the chief operating officer now directly owns 104,512 shares of the company’s stock, valued at approximately $10,380,131.84. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Jeff Reibel sold 1,921 shares of the stock in a transaction that occurred on Monday, August 20th. The shares were sold at an average price of $94.12, for a total transaction of $180,804.52. Following the completion of the sale, the senior vice president now directly owns 8,125 shares in the company, valued at $764,725. The disclosure for this sale can be found here. Corporate insiders own 6.80% of the company’s stock.
LHC Group stock opened at $91.43 on Thursday. The company has a market cap of $2.69 billion, a price-to-earnings ratio of 37.78, a price-to-earnings-growth ratio of 1.34 and a beta of 0.52. LHC Group, Inc. has a 52-week low of $58.65 and a 52-week high of $103.79. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.18.
LHC Group (NASDAQ:LHCG) last announced its quarterly earnings data on Wednesday, October 31st. The health services provider reported $0.95 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.95. LHC Group had a net margin of 3.75% and a return on equity of 8.33%. The company had revenue of $507.00 million for the quarter, compared to the consensus estimate of $515.03 million. During the same period in the prior year, the firm posted $0.64 EPS. The company’s quarterly revenue was up 88.0% compared to the same quarter last year. Equities analysts expect that LHC Group, Inc. will post 3.52 earnings per share for the current fiscal year.
A number of research firms have issued reports on LHCG. SunTrust Banks increased their target price on shares of LHC Group to $115.00 and gave the stock a “buy” rating in a report on Thursday, September 13th. BidaskClub lowered shares of LHC Group from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 10th. Jefferies Financial Group increased their target price on shares of LHC Group to $120.00 and gave the stock a “buy” rating in a report on Friday, August 3rd. Oppenheimer increased their target price on shares of LHC Group from $85.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, August 2nd. Finally, Zacks Investment Research upgraded shares of LHC Group from a “sell” rating to a “hold” rating and set a $104.00 target price on the stock in a report on Saturday, August 4th. Four investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $103.00.
LHC Group Company Profile
LHC Group, Inc, a health care provider, specializes in the post-acute continuum of care primarily for Medicare beneficiaries in the United States. The company operates through four segments: Home Health Services, Hospice Services, Community-Based Services, and Facility-Based Services. The Home Health Services segment offers home nursing services, including wound care and dressing changes, cardiac rehabilitation, infusion therapy, pain management, pharmaceutical administration, skilled observation and assessment, and patient education; medically-oriented social services; and physical, occupational, and speech therapy services.
Featured Article: What Does Beta Mean In Stock Selection
Want to see what other hedge funds are holding LHCG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LHC Group, Inc. (NASDAQ:LHCG).
Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with MarketBeat.com's FREE daily email newsletter.